A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors

Inclusion Criteria:

- Participants who are 16 to 17 years old would be enrolled after consultation with the
Medical Monitor

- Histologically or cytologically documented, incurable or metastatic solid tumor or
hematologic malignancy that is advanced (non-resectable) or recurrent and progressing
since the last anti-tumor therapy and for which no recognized standard curative
therapy exists

- Representative tumor specimens in paraffin blocks (preferred) or at least 15 unstained
slides, with an associated pathology report

- Adequate hematologic and end organ function

- Measurable disease per RECIST v1.1 for participants with solid malignancies.
Disease-specific criteria for participants with prostate cancer, glioblastoma
multiforme (GBM), malignant lymphoma, or multiple myeloma

- For women of childbearing potential: agreement to remain abstinent or use
contraceptive methods

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

- For participants who will undergo serial biopsy in dose-escalation cohort, baseline
tumor tissue samples should be of core needle biopsies for deep tumor tissue or organs
or excisional or punch biopsies for cutaneous or subcutaneous lesions (>/=5 millimeter
[mm] in diameter amenable to serial biopsy)

Exclusion Criteria:

- Known primary central nervous system (CNS) malignancy or symptomatic CNS metastases

- Known hypersensitivity to pharmaceuticals produced in Chinese hamster ovary cells or
any component of the atezolizumab formulation

- History or risk of autoimmune disease (for example, systemic lupus erythematosus,
rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with
antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Bell's palsy,
Guillain-Barré syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis,
or glomerulonephritis)

- History of human immunodeficiency virus (HIV) infection, active hepatitis B (chronic
or acute), or hepatitis C infection

- Signs or symptoms of infection within 2 weeks prior to Cycle 1, Day 1

- Malignancies other than disease under study within 5 years prior to Cycle 1, Day 1

- Participants with prior allogeneic bone marrow transplantation or prior solid organ
transplantation